Literature DB >> 20566220

Porcine circovirus type 2 (PCV2) Cap and Rep proteins are involved in the development of cell-mediated immunity upon PCV2 infection.

Maria Fort1, Marina Sibila, Miquel Nofrarías, Eva Pérez-Martín, Alex Olvera, Enric Mateu, Joaquim Segalés.   

Abstract

The aim of the present study was to investigate the role of the capside (Cap) and replicase (Rep) proteins of Porcine circovirus type 2 (PCV2) as well as the whole PCV2 (both PCV2a and PCV2b genotypes) in the induction of cell-mediated immunity upon infection. At 6 weeks of age, six pigs were intranasally inoculated with the Stoon 1010 (Stoon) isolate (PCV2a) and seven with the Sp-7-10-54-13 (Sp) isolate (PCV2b). None of the pigs developed clinical disease but the Sp group had significantly higher proportion of pigs with PCV2-associated lesions and PCV2 load in tissues compared to the Stoon group. In both groups, development of IFN-gamma secreting cells (SC) in response to the whole PCV2 and Cap protein was detected by means of an ELISPOT from day 7 post-inoculation (PI) to the end of the study (21 days PI). Significant responses against Rep protein were only detected in Sp-inoculated pigs. No differences in ELISPOT results were seen when either PCV2a or PCV2b was used in vitro to recall peripheral blood mononuclear cells (PBMC) in any group. Stimulation of PBMC with the whole virus but not with Cap or Rep protein induced IL-10-SC in all pigs regardless of their PCV2 infection status, indicating an innate origin of this response. The results from this study demonstrate that PCV2-infected pigs developed cell-mediated immunity to Cap and Rep proteins and that, in the course of a sub-clinical infection, development and strength of such responses are possibly related to the levels of PCV2 replication. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566220     DOI: 10.1016/j.vetimm.2010.05.013

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  18 in total

1.  Effect of sow vaccination against porcine circovirus type 2 (PCV2) on virological profiles in herds with or without PCV2 systemic disease.

Authors:  Alfonso Lopez-Rodriguez; Jeroen Dewulf; Tom Meyns; Rubén Del-Pozo-Sacristán; Christine Andreoni; Anne Goubier; Ludivine Chapat; Catherine Charreyre; François Joisel; Dominiek Maes
Journal:  Can Vet J       Date:  2016-06       Impact factor: 1.008

2.  Estimated quantity of swine virus genomes based on quantitative PCR analysis in spray-dried porcine plasma samples collected from multiple manufacturing plants.

Authors:  Elena Blázquez; Joan Pujols; Joaquim Segalés; Carmen Rodríguez; Joy Campbell; Louis Russell; Javier Polo
Journal:  PLoS One       Date:  2022-05-23       Impact factor: 3.752

Review 3.  Current understanding of genomic DNA of porcine circovirus type 2.

Authors:  Qi-Zhuang Lv; Kang-Kang Guo; Yan-Ming Zhang
Journal:  Virus Genes       Date:  2014-07-11       Impact factor: 2.332

4.  Evaluation of the capability of the PCV2 genome to encode miRNAs: lack of viral miRNA expression in an experimental infection.

Authors:  Fernando Núñez-Hernández; Lester J Pérez; Gonzalo Vera; Sarai Córdoba; Joaquim Segalés; Armand Sánchez; José I Núñez
Journal:  Vet Res       Date:  2015-05-01       Impact factor: 3.683

5.  Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge.

Authors:  Hwi Won Seo; Changhoon Park; Kiwon Han; Chanhee Chae
Journal:  Vet Res       Date:  2014-02-02       Impact factor: 3.683

6.  Pigs naturally exposed to porcine circovirus type 2 (PCV2) generate antibody responses capable to neutralise PCV2 isolates of different genotypes and geographic origins.

Authors:  Sherry Kurtz; Llorenç Grau-Roma; Martí Cortey; Maria Fort; Fernando Rodríguez; Marina Sibila; Joaquim Segalés
Journal:  Vet Res       Date:  2014-03-06       Impact factor: 3.683

7.  Identification of microRNAs in PCV2 subclinically infected pigs by high throughput sequencing.

Authors:  Fernando Núñez-Hernández; Lester J Pérez; Marta Muñoz; Gonzalo Vera; Anna Tomás; Raquel Egea; Sarai Córdoba; Joaquim Segalés; Armand Sánchez; José I Núñez
Journal:  Vet Res       Date:  2015-03-03       Impact factor: 3.683

8.  PCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection.

Authors:  Hanna C Koinig; Stephanie C Talker; Maria Stadler; Andrea Ladinig; Robert Graage; Mathias Ritzmann; Isabel Hennig-Pauka; Wilhelm Gerner; Armin Saalmüller
Journal:  Vet Res       Date:  2015-03-03       Impact factor: 3.683

9.  Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo.

Authors:  Robert Patterson; Thomas Eley; Christopher Browne; Henny M Martineau; Dirk Werling
Journal:  Vaccine       Date:  2015-10-21       Impact factor: 3.641

10.  Memory T cell proliferative responses and IFN-γ productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease.

Authors:  Luca Ferrari; Paolo Borghetti; Elena De Angelis; Paolo Martelli
Journal:  Vet Res       Date:  2014-04-16       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.